Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

44.38 -0.47 (-1.04%)

Streaming Delayed Price Updated: 3:11 PM EST, Dec 29, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	401,227
Open	44.49
Bid (Size)	44.37 (200)
Ask (Size)	44.42 (100)
Prev. Close	44.84
Today's Range	44.20 - 45.08
52wk Range	26.74 - 46.60
Shares Outstanding	63,562,303
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...

Via PredictStreet

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Performance

YTD	+10.5%	+10.5%
1 Month	-0.8%	-0.8%
3 Month	+13.6%	+13.6%
6 Month	+41.8%	+41.8%
1 Year	+15.2%	+15.2%

More News

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

December 05, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 04, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

Via The Motley Fool

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Via The Motley Fool

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

Via The Motley Fool

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

Via The Motley Fool

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

Via The Motley Fool

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Via The Motley Fool

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

December 03, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

November 25, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon to Present at Upcoming Investor Conferences

November 06, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

November 03, 2025

Via Chartmill

Xenon Reports Third Quarter 2025 Financial Results & Business Update

November 03, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Insights into Xenon Pharmaceuticals's Upcoming Earnings ↗

October 31, 2025

Via Benzinga

Xenon to Report Q3 2025 Financial Results on November 3, 2025

October 27, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

October 16, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

September 25, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Design Therapeutics Appoints Justin Gover to Board of Directors

September 10, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 29, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Reports Second Quarter 2025 Financial Results & Business Update

August 11, 2025

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?

Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.

What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?

Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?

The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market

What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?

The current price of Xenon Pharmaceuticals Inc. - Common Shares is 44.38

When was Xenon Pharmaceuticals Inc. - Common Shares last traded?

The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 12/29/25 03:11 PM ET

What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?

The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 2.82B

How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?

Xenon Pharmaceuticals Inc. - Common Shares has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.